(Total Views: 247)
Posted On: 05/21/2023 10:47:33 AM
Post# of 590
Frustration with our PMA application is understood and shared.
Yet the market opportunity is still present and growing IMO!
FWIW there is plenty of need and support for the hemostasis need in the surgical
setting.
"The global hemostats market was valued at $2.8 billion in 2021 , and is projected to reach $4.7 billion by 2031, growing at a CAGR of 5.3% from 2022 to 2031. Hemostat is referred to a surgical agent that regulates and controls the bleeding process during surgical procedures."
https://www.mordorintelligence.com/industry-r...cts-market
Notice Baxter and Abott both of whom could be interested in a buyout or partnership.
Stay the course and buy the cheap shares while the price is depressed IMO!
$5-$10+
Yet the market opportunity is still present and growing IMO!
FWIW there is plenty of need and support for the hemostasis need in the surgical
setting.
"The global hemostats market was valued at $2.8 billion in 2021 , and is projected to reach $4.7 billion by 2031, growing at a CAGR of 5.3% from 2022 to 2031. Hemostat is referred to a surgical agent that regulates and controls the bleeding process during surgical procedures."
https://www.mordorintelligence.com/industry-r...cts-market
Notice Baxter and Abott both of whom could be interested in a buyout or partnership.
Stay the course and buy the cheap shares while the price is depressed IMO!
$5-$10+
(0)
(0)
